A Novel Paradigm for Immuno-Oncology Therapeutics: Overcoming Low Response Rates
ALiCE, produced in a 2-by-1 format, is designed to mainly target the surface of cancer cells in the body, as the tumor antigen-binding titers were increased to levels much higher than that of the CD3 antibody. Also, by lowering the binding affinity of the CD3 antibody, excessive T cell activation in the blood has been minimized.
Antibody Like Cell Engager (ALiCE): Our Proprietary Bispecific T Cell Engager Structure that Binds Bivalently to Antigens on Cancer Cells and Monovalently to T Cells
As a typical Y-shaped IgG-type bispecific antibody, antibody modification based on structural engineering is minimized, making ALiCE a platform technology with the most natural bispecific antibody structure.
The upper portion of ALiCE, which maintains the structure of general antibodies, consists of bivalent Fab regions that recognize a target antigen on cancer cells. The crystallizable fragment (Fc) region of the antibody, however, is substituted with a monovalent variable fragment (Fv) region from a CD3-targeting antibody
Satisfying Unmet Medical Needs by Preventing Immune Escape and Specifically Recognizing and Killing Only Tumor Cells
ALiCE first binds to the target antigen on the surface of cancer cells through high affinity, bivalent binding. ALiCE then binds to CD3 present on CD8+ cytotoxic T cells near the cancer cell, resulting in the formation of an immune synapse and stimulating the T cell to become activated to kill the cancer cell even without the TCR-MHC binding signal.